| |APRIL 20269COSMO'S MALE HAIR LOSS TREATMENT DELIVERS SUSTAINED GROWTH OVER TIMEAI CHATBOTS GIVE INACCURATE MEDICAL INFO, STUDY WARNSAI CHATBOTS GIVE INACCURATE MEDICAL INFO, STUDY WARNSALEMBIC PHARMA RECEIVED APPROVAL FOR GENERIC METHOTREXATE INJECTIONHIDDEN DNA MUTATIONS IN IMMUNE CELLS MAY TRIGGER AUTOIMMUNITYCosmo Pharmaceuticals has reported encouraging results for its male hair loss treatment, clascoterone, showing sustained hair growth over a full year in its latest clinical study released today.The topical therapy, aimed at treating androgenetic alopecia, demonstrated that continued use leads to stronger and longer-lasting results compared to shorter treatment periods.According to the company, patients who applied the treatment for 12 months experienced significantly higher hair growth than those who stopped after six months.The data showed a 2.39 times greater improvement in hair count among long-term users, reinforcing the need for consistent use to maintain visible results. Participants who discontinued early saw a decline in hair density, indicating that stopping treatment reverses progress. POA new study has raised concerns about how reliable AI chatbots are when it comes to providing medical information. The research found that many of their responses can be inaccurate medical advice or incomplete, which could mislead users seeking health guidance.The study, published in BMJ Open, examined five popular artificial intelligence tools developed by major technology companies. Researchers tested how well these tools could answer common health-related queries on topics like cancer, vaccines, and nutrition. In total, around 250 responses were analysed. POIndia's radiotherapy device market is entering a high-growth phase, driven by a sharp rise in cancer cases, expanding healthcare infrastructure, and increased public investment in oncology care.Industry estimates indicate the market could more than double over the next decade, signaling a structural shift in how cancer treatment is delivered across the country.Market Poised to Double in ValueRecent industry analyses project that India's radiotherapy device market will grow from roughly USD 150 million in 2024 to nearly USD 390 million by 2033­2034, reflecting a compound annual growth rate (CAGR) of around 9­12 percent.Some broader estimates, which include related radiation oncology systems, suggest the market could reach over USD 700 million by 2032, underlining the scale of investment expected in this segment. POAlembic Pharmaceuticals has secured a key USFDA approval for its generic Methotrexate injection, marking another step in its expansion in the United States market.The approval, granted by the US Food and Drug Administration, allows A groundbreaking study published in the journal Nature has provided the strongest evidence yet that acquired (somatic) DNA mutations in immune cells may be a key driver of autoimmune diseases. Researchers from the Wellcome Sanger Institute, University of Cambridge, and collaborating institutions used ultra-sensitive sequencing to uncover how these mutations disable natural "brakes" on the immune system, allowing it to attack healthy tissues, particularly in autoimmune thyroid diseases like Hashimoto's thyroiditis and Graves' disease. POthe company to market the drug in multiple strengths, strengthening its position in the high-value injectable segment.The approved product is a generic Methotrexate injection, used in the treatment of several cancers and autoimmune disorders.It will be available in 50 mg/2 mL multi-dose vials and 1 g/40 mL single-dose vials. The drug is widely prescribed for conditions such as leukemia, breast cancer, and rheumatoid arthritis, making it a critical addition to Alembic's portfolio. PO
< Page 8 | Page 10 >